BioVie Invited to Present Data on Bezisterim at NIH's RECOVER-TLC Workshop
BioVie Inc. has been invited to present clinical data on its investigational therapy, bezisterim, at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.
Stocks · News reference
KEYS stock rose 3% in pre-market trading due to strong financial results and guidance. Other gainers include TNON, BIVI, ZNB, MSS, CAST, RCON, TGL, OPHC, and GURE. Losers include DAIC, PFSA, TPET, and OSRH with significant declines.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BioVie Inc. has been invited to present clinical data on its investigational therapy, bezisterim, at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the presentation of
FreeCast has appointed Larry Watzman, an advertising executive with experience at major networks including FOX, CBS, NBC, and Scripps, to advance its Zer0Gap Ads streaming monetization platform.
FreeCast, Inc. CEO William Mobley appeared on the 'New to The Street' broadcast on Bloomberg Television to detail the company's streaming infrastructure business and introduce its new 'partner-enabled addressable customers' (PEAC) metric.